

Supplementary Table S2 Number of randomised controlled trials reporting specific adverse reactions related to system organ class and preferred term

System organ class	Preferred term	Number of RCTs (%)
General disorders and administration site conditions	Pain	35 (16.5)
	Flushing	26 (12.3)
	Swelling	18 (8.5)
	Oedema	3 (1.4)
	Pyrexia	3 (1.4)
	Tenderness	2 (1.0)
	Fatigue	1 (0.5)
	Discomfort	1 (0.5)
Skin and subcutaneous tissue disorders	Paraesthesia	7 (3.3)
	Hypoaesthesia	7 (3.3)
	Skin discomfort	7 (3.3)
	Contusion	6 (2.8)
	Erythema	5 (2.4)
	Rash	2 (1.0)
	Skin injury	1 (0.5)
	Skin abrasion	1 (0.5)
	Alopecia	1 (0.5)
	Skin irritation	1 (0.5)
	Hyperhidrosis	1 (0.5)
	Pallor	1 (0.5)
	Skin burning sensation	1 (0.5)
	Sensitive skin	1 (0.5)
Vascular disorders	Haematoma	9 (4.3)
	Skin haemorrhage	8 (3.8)
	Ecchymosis	8 (3.8)
	Petechiae	7 (3.3)
	Orthostatic hypotension	1 (0.5)
	Haematuria	1 (0.5)
	Haemospermia	1 (0.5)
	Penile haemorrhage	1 (0.5)
Vasodilatation	1 (0.5)	
Nervous system disorders	Dizziness	5 (2.4)
	Headache	4 (1.9)
	Neuropathy peripheral	2 (1.0)
	Dyssomnia	1 (0.5)
	Migraine	1 (0.5)
	Tremor	1 (0.5)
	Syncope	1 (0.5)
Gastrointestinal disorders	Nausea	10 (4.7)
	Abdominal discomfort	2 (1.0)
Musculoskeletal and connective tissue disorders	Arthralgia	3 (1.4)
	Myalgia	2 (1.0)
	Hypertonia	1 (0.5)
	Joint dislocation	1 (0.5)
	Joint effusion	1 (0.5)
	Joint stiffness	1 (0.5)
	Muscular weakness	1 (0.5)
Infections and infestations	Infection	2 (1.0)
General system disorders	Asthenia	1 (0.5)
Renal and urinary disorders	Dysuria	1 (0.5)
Cardiac disorders	Palpitations	1 (0.5)
Immune system disorders	Hypersensitivity	1 (0.5)
Respiratory, thoracic and mediastinal disorders	Nasal discomfort	1 (0.5)

Note: RCTs, randomised controlled trials.